Earlier this week I was with a biotech start-up whose investors have been pondering whether a China strategy makes sense.  Their early focus on China has largely been related to whether they could raise capital from Chinese investors.  While they are a start-up, over $40 million has already been invested.  Their first molecule showed good [...]

This was not the original topic for today’s scheduled column, but over the course of the last 24 hours between Damjan’s column yesterday on the Lin v. Siemens case and its impact on FCPA issues specific to healthcare companies in China, a client conversation, and an email forwarded to me by a friend in China [...]

One of our hopes for this blog is that we can blend the strategic (China’s healthcare reforms) with the practical (how to adjust your pricing or distribution strategy as a pharma or device company).  Emphasizing only the former runs the risk of constantly talking up the opportunity inherent with the massive influx of government-led investment [...]

One of the many elements to the senior care industry I have really come to respect and love is its emphasis on taking care of people and an elevated perspective on human dignity, even during periods of life when keeping these front and center can be easy to lose sight of.  For all the market [...]

This post is written with two audiences in mind.  First, and most specifically, are operators and investors eager to expand into China’s senior care market.  Second, and more generally, are businesses and investors interested in profiting from China’s massive healthcare reforms.  The latter group is diverse and includes companies from pharma to diagnostics, from private [...]